AEGERION PHARMACEUTICALS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 7th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 5th day of October, 2010 (the “Effective Date”), between Aegerion Pharmaceuticals, Inc. a Delaware corporation (the “Company”), and William H. Lewis, an individual who currently resides at 22 Canterbury Lane, Summit, NJ 07901, (the “Executive”) (together the “Parties”).
NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR ASSIGNED IN THE...Subordination Agreement • October 7th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS NOTE IS SUBJECT TO A FOURTH AMENDED AND RESTATED SUBORDINATION AGREEMENT DATED OCTOBER 1, 2010 BETWEEN THE COMPANY AND HERCULES TECHNOLOGY GROWTH CAPITAL, INC., A COPY OF WHICH MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE COMPANY.
LICENSE AGREEMENTLicense Agreement • October 7th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
The following patent applications shall also be treated as “Bayer Patent Rights” under this Agreement, provided that any of the following patent applications may have lapsed, may have been cancelled, or are otherwise no longer still pending as of the Effective Date:
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 7th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of March 20, 2007 and is entered into by and between AEGERION PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), with its chief executive office and principal place of business located at 1140 Route 22 East, Suite 304, Bridgewater, NJ 08807 and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”), with its principal place of business located at 400 Hamilton Avenue, Palo Alto, CA 94301.
AEGERION PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED NOTE PURCHASE AGREEMENT October 1, 2010Note Purchase Agreement • October 7th, 2010 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS FOURTH AMENDED AND RESTATED NOTE PURCHASE AGREEMENT (the “Agreement”) is made as of October 1, 2010 (the “Effective Date”) by and among Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons and entities named on the Schedule of Purchasers attached hereto as Schedule I (individually, a “Purchaser” and collectively, the “Purchasers”).
